Materiality
70.25
Source
External coverage
Decided
2026-08-02
Reported $400 billion merger talks between AstraZeneca and Bristol Myers Squibb create asymmetric, terms-dependent issuer impacts.
Reported $400 billion merger talks between AstraZeneca and Bristol Myers Squibb create asymmetric, terms-dependent issuer impacts.
We are still collecting relevant articles for BMY. Curated events highlight the most material developments impacting this ticker right now.